echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > Dig Dis: The effectiveness and feasibility of magnifying endoscopy combined with blue laser imaging in the diagnosis of gastric tumor demarcation without biopsy confirmation

    Dig Dis: The effectiveness and feasibility of magnifying endoscopy combined with blue laser imaging in the diagnosis of gastric tumor demarcation without biopsy confirmation

    • Last Update: 2021-07-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Accurate diagnosis of the dividing line (DL) of gastric tumors is essential for the complete resection of the tumor through endoscopic submucosal dissection (ESD)
    .
    Before ESD, it was controversial to diagnose DL in gastric tumors only through endoscopy

    .
    Recently, a prospective single-center study evaluated the diagnostic accuracy of DL in gastric adenomas and well-differentiated adenocarcinomas using only magnifying endoscopy combined with blue laser imaging (M-BLI) and concurrent use of M-BLI and biopsy to confirm the diagnosis of gastric adenomas and well-differentiated adenocarcinomas.
    , The research results have been published in Dig Dis

    .

    diagnosis

    Between July 2015 and December 2016, the study included 96 well-differentiated adenocarcinomas and 32 gastric adenomas
    .
    A total of 122 lesions with clear DL on M-BLI were randomly assigned to receive only M-BLI (M-BLI group) or M-BLI and biopsy confirmation (M-BLI-BC group).
    ≈5 mm of non-cancerous tissue for biopsy in 4 directions

    .
    The main purpose is to determine whether M-BLI without biopsy confirmation has a disadvantage compared with M-BLI with biopsy confirmation in terms of diagnostic accuracy and complete resection

    .

     

    The results showed that there were no significant differences between the two groups in terms of gender, median age, skin color, circumference, gross type, diagnosis based on biopsy, and Helicobacter pylori infection
    .
    The diagnostic accuracy of DL in the M-BLI and M-BLI-BC groups were 100 and 95.
    0%, respectively, and the complete resection rate was 100%

    .

    Infect

    In summary, the results of this study show that the diagnostic ability of M-BLI is very good in diagnosing the boundary between gastric adenoma and well-differentiated adenocarcinoma
    .
    For these lesions, DL confirmed by M-BLI does not need to be confirmed by biopsy

    .

     

    Original source:

     

    Takahiro Nakano, et al.
    ,
    Efficacy and Feasibility of Magnifying Blue Laser Imaging without Biopsy Confirmation for the Diagnosis of the Demarcation of Gastric Tumors: A Randomized Controlled Study .
    Dig Dis.
    2021;39(2):156-164.
    doi: 10.
    1159 /000510559.
     

    Efficacy and Feasibility of Magnifying Blue Laser Imaging without Biopsy Confirmation for the Diagnosis of the Demarcation of Gastric Tumors: A Randomized Controlled Study

    in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.